You are currently viewing a new version of our website. To view the old version click .
MDPIMDPI
Search all articles
by
  • Thi-Thao-Linh Nguyen and
  • Van-An Duong*

Reviewer 1: Anonymous Reviewer 2: Gábor Katona

Round 1

Reviewer 1 Report

In the entry: “Solid lipid nanoparticles” the authors provided an overview of solid lipid nanoparticles (SLNs) by summarizing the primary features of SLNs, methods to prepare SLNs, and recent applications of SLNs in drug delivery.

Please take into consideration the following remarks:

  1. I’ve observed in the whole manuscript the tendency of textbook/Wikipedia-style writing. In some cases, the information is enumerated in sentences that are not connected. E.g.:

- the first paragraph from the introduction;

- lines 61-77;

- the whole sub-section 2.2.;

- and so on.

  1. The introduction is too short. I recommend you to add more data about Nanotechnology-based drug delivery systems, what are the main advantages and disadvantages of each one, and why have you chosen SLNs?
  2. 2.1. Structural Features and General Components of SLNs – I suggest you to add a figure with the SLNs structure.
  3. Lines 61-77: I recommend you to add this data in a table, with references for each ingredient. There are only two references in this paragraph, very few to sustain all this important data.
  4. 2.2. Physicochemical Characterization – I suggest you to re-organize some data from this sub-section in a scheme (such as Figure 1) or table.
  5. 3. Methods for SLNs Preparation – Also in this case, some data from this section can be re-organized in a table. In this way, the manuscript will be more readable.
  6. Try to improve Figure 1, it seems to be not professional, is more like an image for a usual website. Try to improve it in order to make it more scientific.
  7. Conclusions and Prospects – lines 547-550: this data can be added in a sub-section before Conclusions, concerning the actual status of lipid-based nanoparticles in clinical practice. Have you searched if there are also clinical trials regarding the use of this nanoparticles for drug delivery?

Author Response

May 11th, 2022

Dear Reviewer,

We appreciate the valuable time and the constructive comments of the  Reviewers. We revised the manuscript according to the review comments and responded to each comment. The responses to reviewer comments are detailed below. All revisions in the revised manuscript are marked by the Track Change function of MS. Word.

Reviewer 1

In the entry: “Solid lipid nanoparticles” the authors provided an overview of solid lipid nanoparticles (SLNs) by summarizing the primary features of SLNs, methods to prepare SLNs, and recent applications of SLNs in drug delivery.

Please take into consideration the following remarks:

  1. I’ve observed in the whole manuscript the tendency of textbook/Wikipedia-style writing. In some cases, the information is enumerated in sentences that are not connected. E.g.:

- the first paragraph from the introduction;

- lines 61-77;

- the whole sub-section 2.2.;

- and so on.

Response: We are thankful for the constructive comments of the reviewer. We revised the manuscript according to the comments. Please see lines 20-26, 30-61, and 117-123.

 

  1. The introduction is too short. I recommend you to add more data about Nanotechnology-based drug delivery systems, what are the main advantages and disadvantages of each one, and why have you chosen SLNs?

Response: We agree with the reviewer's comments. We revised the Introduction section accordingly by adding more information on nanotechnology-based drug delivery systems, their advantages and disadvantages. Please see lines 19-61.

 

  1. 2.1. Structural Features and General Components of SLNs – I suggest you to add a figure with the SLNs structure.

Response: We added Figure 1 to illustrate the structure of SLNs.

 

  1. Lines 61-77: I recommend you to add this data in a table, with references for each ingredient. There are only two references in this paragraph, very few to sustain all this important data.

Response: We are thankful for the constructive comments of the reviewer. We revised the section and included Table 1 as suggested.

 

  1. 2.2. Physicochemical Characterization – I suggest you to re-organize some data from this sub-section in a scheme (such as Figure 1) or table.

Response: According to the comment, we added Table 2 in the manuscript to summarize the physicochemical characterization of the SLNs.

 

  1. 3. Methods for SLNs Preparation –Also in this case, some data from this section can be re-organized in a table. In this way, the manuscript will be more readable.

Response: We are thankful for the constructive comments of the reviewer. We added Table 3 to summarize the primary features of each method.

 

  1. Try to improve Figure 1, it seems to be not professional, is more like an image for a usual website. Try to improve it in order to make it more scientific.

Response: We agree with the comments of the reviewer. Since the structure of SLNs is shown in the new Figure 1, the illustration of drug incorporation in the old Figure 1 is unnecessary. Therefore, it was omitted.

 

  1. Conclusions and Prospects – lines 547-550: this data can be added in a sub-section before Conclusions, concerning the actual status of lipid-based nanoparticles in clinical practice. Have you searched if there are also clinical trials regarding the use of this nanoparticles for drug delivery?

Response: We are thankful for the constructive comments of the reviewer. We added sub-section 4.7 to provide information on the clinical status of the lipid-based nanoparticles, as suggested. We also found one clinical trial of an SLN formulation.

Reviewer 2 Report

The entry entitled “Solid lipid nanoparticles” by Thi-Thao-Linh Nguyen and Van-An Duong deals with a general characterization of SLNs and its nanomedical applications. The entry is well constructed, easy to read and provides useful information for the reader. I only have few concerns, which should be take into consideration:

 

Please provide a Figure about structural features of SLNs, to make it more conceivable for the reader.

I suggest to put the general ingredients in a table, rather listing them in the continuous text.

The authors mention, in Line 87 laser diffraction is a usually applied method for determination of particles size of SLNs. Please highlight that this method rather suitable for estimation of particle size of nanoparticles, the Brownian motion-based size determination via DLS is more sensitive for that purpose.

Be careful mRNA-based vaccines consist of rather liposomes than SLNs, in present context it is misleading. Please clarify it or provide more information regarding the role of SLNs in vaccine development if possible.

Author Response

May 11th, 2022

Dear Reviewer,

We appreciate the valuable time and the constructive comments of the  Reviewers. We revised the manuscript according to the review comments and responded to each comment. The responses to reviewer comments are detailed below. All revisions in the revised manuscript are marked by the Track Change function of MS. Word.

 

Reviewer 2

The entry entitled “Solid lipid nanoparticles” by Thi-Thao-Linh Nguyen and Van-An Duong deals with a general characterization of SLNs and its nanomedical applications. The entry is well constructed, easy to read and provides useful information for the reader. I only have few concerns, which should be take into consideration:

 

  1. Please provide a Figure about structural features of SLNs, to make it more conceivable for the reader.

Response: We are thankful for the constructive comments of the reviewer. We added Figure 1 to illustrate the structure of SLNs.

 

  1. I suggest to put the general ingredients in a table, rather listing them in the continuous text.

Response: We agree with the comments of the reviewer. We revised the section and included Table 1 as suggested.

 

  1. The authors mention, in Line 87 laser diffraction is a usually applied method for determination of particles size of SLNs. Please highlight that this method rather suitable for estimation of particle size of nanoparticles, the Brownian motion-based size determination via DLS is more sensitive for that purpose.

Response: We agree with the reviewer that DLS is more sensitive and accurate in determining the particle size of SLNs. We added some sentences to highlight the issue as suggested. Please see lines 117-123.

 

  1. Be careful mRNA-based vaccines consist of rather liposomes than SLNs, in present context it is misleading. Please clarify it or provide more information regarding the role of SLNs in vaccine development if possible.

Response: We agree with the comments of the reviewer. These mRNA-based vaccines are lipid nanoparticles with liposome-like structures; they are not SLNs. We added sub-section 4.7 to provide information on the clinical status of the lipid-based nanoparticles and include one clinical trial of an SLN formulation.

Round 2

Reviewer 1 Report

The authors considered very carefully all my recommendations. The entry has a superior quality know and can be published. 

Reviewer 2 Report

The authors addressed my concerns in their reply. Thank you for providing me the revised version of manuscript, I checked it and hereby I confirm it can be accepted in present form for publication!